Non-oncologic incidental uptake on FAPI PET/CT imaging
The British Journal of Radiology · 2023-02 · 96 (1142)
DOI: 10.1259/bjr.20220463 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The British Journal of Radiology, 2023-02. Verfasst von Masatoshi Hotta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California, Los Angeles, USA. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Positron-Emission Tomography. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Fibroblast-activation protein (FAP) is a serine protease classified in the dipeptidyl peptidase 4 (DPP4) family. FAP is predominantly expressed in activated fibroblasts such as the cancer-associated fibroblasts (CAFs). FAP expression in CAFs is associated with tumor progression and poor prognosis in solid cancers. Recently, radiolabeled FAP inhibitors (FAPI) has been developed, which enables positron emission tomography (PET) imaging of FAP. FAPI PET/CT can provide a higher tumor-to-background ratio (TBR) than 18 F-fludeoxyglucose PET/CT in various cancers, and thus has attracted substantial attention. As studies on FAPI PET grow in number and size, incidental findings related to non-oncologic conditions have been increasingly reported. FAPI PET uptake has been reported in various conditions such as benign tumors, fibrotic, granulomatosis, scarring/wound, degenerative diseases, and inflammatory diseases. The knowledge of physiological and non-oncologic causes of FAPI uptake is indispensable for accurate FAPI PET/CT interpretation and can help appropriate management of incidental findings on FAPI PET/CT in patients referred for cancer staging indications. In this review article, we describe for each organ system (Brain, Oral mucosa, Salivary Glands, Thyroid, Lung, Myocardium, Breast, Esophagus, Stomach, Intestine, Liver, Gallbladder, Pancreas, Spleen, Kidney, , Uterus, Bone marrow, Joints, Muscle, Vessels, Lymph nodes), the patterns of physiological FAPI uptake and the main causes of non-oncological uptake reported from the literature with FAPI-02, FAPI-04 and FAPI-46. We also illustrate some examples from our institutional database at UCLA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California, Los Angeles, USA.
- Department of Radiological Sciences, University of California Los Angeles, Los Angeles, CA, United States.
ORCID-Profile: Masatoshi Hotta
Zitieren
APA
Hotta, M., Rieger, A. C., Jafarvand, M. G., Menon, N., Farolfi, A., Benz, M. R., & Calais, J. (2023). Non-oncologic incidental uptake on FAPI PET/CT imaging. The British Journal of Radiology, 96(1142). https://doi.org/10.1259/bjr.20220463
Vancouver
Hotta M, Rieger AC, Jafarvand MG, Menon N, Farolfi A, Benz MR, et al. Non-oncologic incidental uptake on FAPI PET/CT imaging. The British Journal of Radiology. 2023;96(1142). doi:10.1259/bjr.20220463
BibTeX
@article{Hotta2023,
author = {Hotta, Masatoshi and Rieger, Angela C and Jafarvand, Mahbod G and Menon, Nandakumar and Farolfi, Andrea and Benz, Matthias R and Calais, Jeremie},
title = {Non-oncologic incidental uptake on FAPI PET/CT imaging},
journal = {The British Journal of Radiology},
year = {2023},
volume = {96},
number = {1142},
doi = {10.1259/bjr.20220463}
}
EUVIMED